Shyam Tanguturi, MD
Radiation Oncology · Boston, MANPI 1992099956
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (33.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 36.1% of the total. Reporting peaked in 2024 at $2,313 and has fallen 78.4% since, to $500 in 2025.
Across 14 payments — averaging $398.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$2K
- Viewray Technologies Inc$2K
- MIM Software Inc.$1K
- IBA Proton Therapy, Inc.$844
- Monteris Medical Corporation$116
- Mevion_medical_systems_inc$30
What the payments were for
- Consulting fees$1,88834%
- Speaking & faculty fees$1,50027%
- Travel & lodging$1,28523%
- Food & beverage$90216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 2 | $2,010 |
| Viewray Technologies Inc | 4 | $1,574 |
| MIM Software Inc. | 1 | $1,000 |
| IBA Proton Therapy, Inc. | 3 | $844 |
| Monteris Medical Corporation | 1 | $116 |
| Mevion_medical_systems_inc | 3 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MRIdian LINAC$1,571
- Maestro$1,000
- Neuroblate$116
How this compares
$5,575 in reported general payments places this provider in the 85th percentile of 200 radiation oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 12 | $446 |
| Dexamethasone | 13 | $193 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Boston
- Peter OrioBoston$1.8M
- Paul NguyenBoston$721K
- Jason EfstathiouBoston$156K
- Jonathan SchoenfeldBoston$53K
- Martin KingBoston$37K
- Raymond MakBoston$36K
- Shannon MacdonaldBoston$33K
- Nima AghdamBoston$29K
- Rachel JimenezBoston$28K
- Theodore HongBoston$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.